In light of the increasing global demand for HMOs, Kyowa Hakko Bio is eyeing opportunities within the Chinese and Thai markets, despite a hazy regulatory environment. Moreover, the company is investing in a new Thai facility to expand its production capacity. Kentaro Yanashima, Research & Business Development for Kyowa Hakko Bio, tells NutritionInsight all about the promising potential of HMO’s for both infant and adult nutrition and the company’s expansion plans.
Upcoming webinars

Introducing LifeChews® and the Next Generation of Plant-based Supplements
Sirio
Register now

Why ARA & DHA matter: Key lipids shaping infant development
dsm-firmenich
Register now

Where Structure Drives Beauty: From Scalp Health to Skin Radiance
Monteloeder
Register now
All upcoming webinars
Subscribe to our newsletters
By continuing to browse our site you agree to our Privacy Statement















